Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma

Magnetic Resonance Imaging

Volumn 31, Issue 5, 2013, Pages 748-754

  Ooka, Yoshihiko ^a   Kanai, Fumihiko ^a   Okabe, Shinichiro ^a   Ueda, Takuya ^b   Shimofusa, Ryota ^b   Ogasawara, Sadahisa ^a   Chiba, Tetsuhiro ^a   Sato, Yasunori ^c   Yoshikawa, Masaharu ^a   Yokosuka, Osamu ^a  

^a Department of Medicine and Clinical Oncology ^*  (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CT angiography; Gadoxetic acid; Hepatocellular carcinoma; Liver; MRI

Indexed keywords

EOB PRIMOVIST; GADOXETIC ACID; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; FEMALE; GRADIENT DUAL ECHO SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PORTAL PHLEBOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; ANGIOGRAPHY; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84877115182     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2012.10.028     Document Type: Article

References (26)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
2. Bruix J., Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005, 42(5):1208-1236.
3. Yuen M.F., Cheng C.C., Lauder I.J., Lam S.K., Ooi C.G., Lai C.L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology (Baltimore, MD) 2000, 31(2):330-335.
4. Matsui O., Takashima T., Kadoya M., Ida M., Suzuki M., Kitagawa K., et al. Dynamic computed tomography during arterial portography: the most sensitive examination for small hepatocellular carcinomas. J Comput Assist Tomogr 1985, 9(1):19-24.
5. Yukisawa S., Okugawa H., Masuya Y., Okabe S., Fukuda H., Yoshikawa M., et al. Multidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver: a comparison with multi-phase CT during hepatic arteriography. Eur J Radiol 2007, 61(2):279-289.
6. Jang H.J., Lim J.H., Lee S.J., Park C.K., Park H.S., Do Y.S. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation?. Radiology 2000, 215(2):373-380.
7. Imai Y., Murakami T., Hori M., Fukuda K., Kim T., Marukawa T., et al. Hypervascular hepatocellular carcinoma: combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008, 38(2):147-158.
8. Inoue E., Fujita M., Hosomi N., Sawai Y., Hashimoto T., Kuroda C., et al. Double-phase CT arteriography of the whole liver in the evaluation of hepatic tumors. J Comput Assist Tomogr 1998, 22(1):64-68.
9. Murakami T., Takamura M., Kim T., Hori M., Federle M.P., Onishi H., et al. Double-phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma. Eur J Radiol 2005, 54(2):246-252.
10. Hamm B., Staks T., Muhler A., Bollow M., Taupitz M., Frenzel T., et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995, 195(3):785-792.
11. Ahn S.S., Kim M.J., Lim J.S., Hong H.S., Chung Y.E., Choi J.Y. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010, 255(2):459-466.
12. Chou C.T., Chen Y.L., Wu H.K., Chen R.C. Characterization of hyperintense nodules on precontrast T1-weighted MRI: utility of gadoxetic acid-enhanced hepatocyte-phase imaging. J Magn Reson Imaging 2011, 33(3):625-632.
13. Bluemke D.A., Sahani D., Amendola M., Balzer T., Breuer J., Brown J.J., et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005, 237(1):89-98.
14. Halavaara J., Breuer J., Ayuso C., Balzer T., Bellin M.F., Blomqvist L., et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006, 30(3):345-354.
15. Kim Y.K., Kim C.S., Han Y.M., Kwak H.S., Jin G.Y., Hwang S.B., et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr 2009, 33(6):844-850.
16. Ichikawa T., Saito K., Yoshioka N., Tanimoto A., Gokan T., Takehara Y., et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010, 45(3):133-141.
17. Di Martino M., Marin D., Guerrisi A., Baski M., Galati F., Rossi M., et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010, 256(3):806-816.
18. Onishi H., Kim T., Imai Y., Hori M., Nagano H., Nakaya Y., et al. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT. Eur Radiol 2012, 22(4):845-854.
19. Akai H., Kiryu S., Matsuda I., Satou J., Takao H., Tajima T., et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011, 80(2):310-315.
20. Martin J., Sentis M., Zidan A., Donoso L., Puig J., Falco J., et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995, 195(1):125-130.
21. Xu P.J., Yan F.H., Wang J.H., Lin J., Ji Y. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis. JMRI 2009, 29(2):341-349.
22. Vandecaveye V., De Keyzer F., Verslype C., Op de Beeck K., Komuta M., Topal B., et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009, 19(10):2456-2466.
23. Sano K., Ichikawa T., Motosugi U., Sou H., Muhi A.M., et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011, 261(3):834-844.
24. Dorfman D.D., Berbaum K.S., Metz C.E. Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method. Invest Radiol 1992, 27(9):723-731.
25. Hillis S.L., Obuchowski N.A., Schartz K.M., Berbaum K.S. A comparison of the Dorfman-Berbaum-Metz and Obuchowski-Rockette methods for receiver operating characteristic (ROC) data. Stat Med 2005, 24(10):1579-1607.
26. Golfieri R., Renzulli M., Lucidi V., Corcioni B., Trevisani F., Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011, 21(6):1233-1242.